• In May 2026, Medline completed a US$2.68 billion follow-on offering of 72,554,594 Class A shares at US$37 each, while also expanding its animal health portfolio with custom spay/neuter surgical packs and supporting shelters like Pensacola Humane Society in scaling high-volume procedures.
• Medline Canada’s first Prime Vendor agreement with Mohawk Medbuy marks the company’s initial Prime Vendor foothold outside the US, highlighting how its supply chain capabilities and product innovation are being extended into new geographies and adjacent markets such as animal health.
• We’ll now examine how Medline’s first Canadian Prime Vendor deal reshapes the company’s investment narrative and long-term growth drivers.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Medline Investment Narrative Recap

To own Medline, you need to believe in its ability to turn a large, contracted customer base and automation investments into sustained earnings growth while managing margin pressure from costs and tariffs. The recent US$2.68 billion follow on offering and Canadian Prime Vendor win do not appear to change the near term focus on executing Prime Vendor conversions, while the biggest risk remains that rising input costs or more punitive tariffs could compress margins if not offset.

The new Prime Vendor agreement with Mohawk Medbuy in Canada looks most relevant for the current narrative, because Prime Vendor wins and conversions are central to Medline’s growth drivers. This contract extends Medline’s stockless distribution and supply chain capabilities into a new geography, directly tying into the company’s push to build a larger contracted base that can support Medline Brand conversions across acute and adjacent markets.

Yet investors should be aware that if rising input costs or tariff changes outpace Medline’s pricing power, then...

Medline's narrative projects $36.6 billion revenue and $2.2 billion earnings by 2029. This requires 7.9% yearly revenue growth and an earnings increase of about $1.2 billion from $966.0 million.

Uncover how Medline's forecasts yield a $51.70 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community cluster in a tight US$46.37 to US$51.70 range, underscoring how differently individual investors can view Medline’s worth. You should weigh those views against the central risk that Prime Vendor wins and conversions, including in Canada, may not ramp as expected, which could influence how the company’s growth potential is ultimately reflected in its share price.

Explore 3 other fair value estimates on Medline - why the stock might be worth just $46.37!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Medline research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Medline research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medline's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 12 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.